Glimitab-MV 1 Tablet is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, leading to a reduction in postprandial hyperglycemia. The synergistic action of these agents provides comprehensive glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Glimitab-MV 1 is typically prescribed when monotherapy or dual therapy with individual agents is insufficient to achieve optimal glycemic targets. It is important to administer the tablet before meals to maximize efficacy and minimize gastrointestinal side effects. Patients should be monitored regularly for blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis. This combination therapy should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring to reduce the risk of long-term diabetic complications.